Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eledon Pharmaceuticals (ELDN) Short-term Investments (2016 - 2026)

Eledon Pharmaceuticals filings provide 2 years of Short-term Investments readings, the most recent being $70000.0 for Q4 2017.

  • On a quarterly basis, Short-term Investments rose 400.0% to $70000.0 in Q4 2017 year-over-year; TTM through Dec 2017 was $70000.0, a 400.0% increase, with the full-year FY2017 number at $70000.0, up 400.0% from a year prior.
  • Short-term Investments hit $70000.0 in Q4 2017 for Eledon Pharmaceuticals, up from $13000.0 in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $70000.0 in Q4 2017 to a low of $13000.0 in Q2 2017.